HCV Advocate LogoHCV Advocate Logo
Contact Us Site Map Resources en Espanol
For living Positivley. Being Well
About Hepatitis
News Updates
News Review
Conference reports
News Articles
HCV Advocate Newsletter
Sign up for Email Updates
Community & Support
Resource Library
About Hcsp
 
Bookmark and Share
News Review

Top News
from EASL 2012

  EASL 2012 Promising Findings for Therapeutic Hepatitis C Vaccine TG4040
May 8

  EASL 2012 Brivanib did not improve overall liver cancer survival, but did show anti-tumour activity
April 30

  EASL 2012 GS-7977 with interferon/ribavirin cures most treatment-naive hepatitis C patients in 12 weeks
April 30

  EASL 2012 TRANSGENE : Reports Positive Follow Up Phase 2 Data on Its HCV Therapeutic Vaccine TG4040
April 23

  EASL 2012 Achillion Clarifies End of Treatment Data From Phase 2a Trial With ACH-1625 Based Regimen in Hepatitis C
April 23

  EASL 2012 Gilead's Hepatitis C Drug Poised To Reach The Market As One Of The First 'All Oral' Combinations
April 22

  EASL 2012 Celebrate the Hep C Wins, for Now
April 21

  EASL 2012 Hepatitis C meds GS-7977, daclatasvir and asunaprevir look good in interferon-free combos
April 21

  EASL 2012 Interferon-lambda as effective as alpha but with much better safety profile in hepatitis C
April 21

  EASL 2012 Presidio Pharmaceuticals Announces a New Clinical Candidate, PPI-383, a Novel Pan-Genotypic Non-Nucleoside Polymerase Inhibitor for HCV
April 21

  EASL 2012 Achillion Announces 94 - 100% Complete EVR From Phase 2 Trial With ACH-1625 Based Regimen in Hepatitis C
April 21

  EASL 2012 Final results from MSD's VICTRELIS plus PEGINTRON Phase III trial on HCV treatment-related anemia
April 20

  EASL 2012 Phase 2b Study of Boehringer Ingelheim's Interferon-Free Hepatitis C Treatment Shows Undetectable Virus in HCV Genotype-1 Patients 12 Weeks After Treatment Ended (SVR12)
April 20

  EASL 2012 Drug interactions won't exclude HCV transplant or HIV co-infected patients from treatment
April 19

  EASL 2012 Recapitulation of the entire hepatitis C virus life in engineered mouse cell lines
April 19

  EASL 2012 All-Oral Hepatitis C Virus Treatment with Bristol-Myers Squibb's Investigational Compounds Daclatasvir and Asunaprevir Achieved Sustained Virologic Response in 77% of Difficult-to-Treat Patients
April 19

  EASL 2012 Idenix Pharmaceuticals Provides Update on Hepatitis C Clinical Development Programs
April 19

  EASL 2012 Gilead Announces Sustained Virologic Response Data for 12-Week Regimen of GS-7977 Plus Pegylated Interferon and Ribavirin in Genotype 1 Hepatitis C Patients
April 19

  EASL 2012 Gilead Announces Early Sustained Virologic Response Rates for GS-7977 Plus Ribavirin in Genotype 1 Treatment-Naïve Hepatitis C Patients
April 19

  EASL 2012 Abbott Presents Positive Results from Interferon-Free Phase 2 "Co-Pilot" Study for the Treatment of Hepatitis C
April 19

  EASL 2012 New Data Suggests Interferon-Free Therapy Around the Corner for HCV Patients
April 19

  EASL 2012 Phase 2b Data Show SVR12 in Cirrhotic HCV Patients Treated with Interferon-Free Regimen
April 19

  EASL 2012 Vertex Advances INCIVEK(TM) (telaprevir) and Broad Portfolio of Medicines in Development With Goal of Further Expanding and Improving Treatment for People With Hepatitis C
April 18

  EASL 2012 Gilead Sciences to Present New Hepatitis B and C Data at European Conference on Liver Disease This Week
April 18

  EASL 2012 INCIVO® (Telaprevir) SVR Rates Unaffected by Ribavirin Dose Reduction in Treatment Naïve and Previously Treated Patients With Genotype-1 Chronic HCV
April 18

 

 


About Hepatitis | News Updates | Community & Support | Resource Library | About HCSP | Contact Us | Site Map | Recursos en Español | Home

Hepatitis C Support Project

© 2012 Hepatitis C Support Project

Medical  Writers' Circle
Fact Sheets